Close

Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/26/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BA
8. SNAP
9. TMUS
10. BIIB


Go back to Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed